Les lymphomes

Jerusalem, Guy; Hustinx, Roland; Beguin, Yves; Depas, Gisèle; Fassotte, Marie-France; De Barsy, Caroline; Foidart, Jacqueline; Fillet, Georges

Request a copy

Article (Scientific journals)

Les lymphomes

Jerusalem, Guy; Hustinx, Roland; Beguin, Yves et al.

2003 • In Médecine Nucléaire: Imagerie Fonctionnelle et Métabolique, 27 (8), p. 401-410

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/14792

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Jerusalem G et al, Méd Nucl Imag Fonct 2003.pdf

Publisher postprint (1.12 MB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Hodgkin Diseases; Lymphomas; Positron emission tomography; FDG; Oncology

Abstract :

[fr] Actuellement, on arrive à guérir 70-80% des patients atteints de maladie de Hodgkin et 50% des patients atteints de lymphome non-Hodgkinien de malignité intermédiaire ou élevée. Une approche systématique concernant le diagnostic, la classification de la maladie et la détermination des facteurs pronostiques permet de choisir la thérapeutique la plus appropriée. Les auteurs passent en revue les examens à réaliser au diagnostic et discutent de la place de la tomographie à émission de positons (TEP) dans cette indication. Ils évoquent ensuite le problème des masses résiduelles. La TEP est maintenant l'examen de choix pour établir le bilan de fin de traitement. Les auteurs discutent également du rôle potentiel de la TEP pour l'évaluation thérapeutique précoce et le suivi régulier des patients après traitement pour lymphome. Enfin, l'aspect particulier des lymphomes de l'enfant est abordé.

Disciplines :

Oncology
Radiology, nuclear medicine & imaging

Author, co-author :

Jerusalem, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale

Hustinx, Roland ; Université de Liège - ULiège > Département des sciences cliniques > Médecine nucléaire

Beguin, Yves ; Université de Liège - ULiège > Département des sciences cliniques > Hématologie - Oncologie médicale

Depas, Gisèle ; Centre Hospitalier Universitaire de Liège - CHU > Médecine nucléaire

Fassotte, Marie-France ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

De Barsy, Caroline

Foidart, Jacqueline ; Centre Hospitalier Universitaire de Liège - CHU > Médecine nucléaire

Fillet, Georges ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Language :

French

Title :

Les lymphomes

Alternative titles :

[en] Lymphomas

Publication date :

2003

Journal title :

Médecine Nucléaire: Imagerie Fonctionnelle et Métabolique

ISSN :

0928-1258

eISSN :

1878-6820

Publisher :

Elsevier, Paris, France

Volume :

Issue :

Pages :

401-410

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 28 January 2010

Statistics

Number of views

158 (17 by ULiège)

Number of downloads

9 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Armitage J, Mauch P, Harris N, Bierman P.Non-Hodgkin's lymphomas, In: De Vita V Jr, Hellman S, Rosenberg S, editors. Cancer: Principles and practice of oncology. Philadelphia: Lippincott Williams and Wilkins, 2001, p. 2256-2316.
Diehl V, Mauch P, Harris N. Hodgkin's disease, In: De Vita V Jr, Hellman S, Rosenberg S, editors. Cancer: Principles and practice of oncology. Philadelphia: Lippincott Williams and Wilkins, 2001, p.2339-2387.
Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989, 7, 1630-1636.
Newman JS, Francis IR, Kaminski MS, Wabl RL. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994, 190, 111-116.
Moog F, Bangerter M, Diederichs CG et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18] fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997, 203, 795-800.
Jerusalem G, Warland V, Najjar F et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Communications 1999, 20, 13-20.
Moog F, Bangerter M, Diederichs CG et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998, 206, 475-481.
Moog F, Bangerter M, Kotzerke J et al. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998, 16, 603-609.
Carr R, Barrington SF, Madan B et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998, 91, 3340-3346.
Jerusalem G, Silvestre RM, Beguin Y et al. Does 18F-FDG PET replace bone marrow biopsy (BMB) in patients with Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL). Blood 2002, 100:768a (abstr. #3039).
Najjar F, Jerusalem G, Paulus P et al. Intérêt clinique de la tomographie à émission de positons dans la détection et le bilan d'extension des lymphomes non Hodgkiniens de malignité intermédiaire ou élevée. Médecine nucléaire Imagerie fonctionnelle et métabolique 1999, 23, 281-290.
Jerusalem G, Beguin Y, Najjar F et al. Positron emission tomography (PET) with 18F-Fluorodeoxyglucose (18F-FDG) for the staging of low grade non-Hodgkin's lymphoma (NHL). Ann Oncol 2001, 825-830.
Jerusalem G, Beguin Y. Positron emission tomography in non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL. Clin Lymphoma 2002, 3, 56-61.
Hoffmann M, Kletter K, Diemling M et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 1999, 10, 1185-1189.
Bangerter M, Moog F, Buchmann I et al. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 1998, 9, 1117-1122.
Weidmann E, Baican B, Hertel A et al. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. Leuk Lymph 1999, 34, 545-551.
Jerusalem G, Beguin Y, Fassotte MF et al. Whole-body positron emission tomography using 18F-fluoro-deoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 2001, 86, 266-273.
Jerusalem G, Beguin Y. Does positron emission tomography have a role in routine clinical practice in patients with Hodgkin's disease ? Clin Lymphoma 2002, 3, 125-126.
Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988, 6, 931-933.
Israel O, Front D, Lam M et al. Gallium 67 imaging in monitoring lymphoma response to treatment. Cancer 1988, 61, 2439-2443.
Wirth A, Seymour JF, Hicks RJ et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 2002, 112, 262-268.
Shen YY, Kao A, Yen RF. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomograpby and gallium-67 citrate scintigrapby for detecting malignant lymphoma. Oncol Rep 2002, 9, 321-325.
Kostakoglu L, Leonard JP, Kuji I et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 2002, 94, 879-888.
Jerusalem G, Beguin Y, Fassotte MF et al. Whole-body positron emission tomography using 18F-fluorodeoxy-glucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999, 94, 429-433.
Zinzani PL, Magagnoli M, Chierichetti F et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 1999, 10, 1181-1184.
Spaepen K, Stroobants S, Dupont P et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001, 19, 414-419.
de Wit M, Bohuslavizki KH, Buchert R et al. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001, 12, 29-37.
Weibrauch MR, Re D, Scheidhauer K et al. Thoracic positron emission tomography using (18)F-fluoro-deoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001, 98, 2930-2934.
Spaepen K, Stroobants S, Dupont P et al. Prognostic value of pretransplant positron emission tomography using fluorine-18-fluorodeoxy-glucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003, in press
Janicek M, Kaplan W, Neuberg D et al. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol 1997, 15, 1631-1637.
Front D, Bar-Shalom R, Mor M et al. Aggressive non-Hodgkin lymphoma: early prediction of outcome with 67Ga scintigraphy. Radiology 2000, 214, 253-257.
Jerusalem G, Beguin Y, Fassotte MF et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 2000, 85, 613-618
Spaepen K, Stroobants S, Dupont P et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002, 13, 1356-1363.
Jerusalem G, Beguin Y, Fassotte MF, et al. Early detection of relapse by whole-body positron emission tomography (PET) in the follow-up of patients with Hodgkin's disease (HD). Ann Oncol 2003, 14, 123-130.
Weinstein H, Tarbell N. Leukemias and lymphomas of childhood, In: De Vita V Jr, Hellman S, Rosenberg S, editors. Cancer: Principles and practice of oncology. Philadelphia: Lippincott Williams and Wilkins, 2001, p. 2235-2256.
Montravers F, McNamara D, Landman-Parker J et al. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med Mol Imaging 2002, 29, 1155-1165.